Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...
Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests...
Zappy Zapolin Hopes To Put Ibogaine Front And Center For Addiction
“The only legitimate addiction interrupter capable of breaking a heroin, meth, opiate, or alcohol addiction in a single 12-hour session.”
Adding Silo Pharma (SILO) $3.50 to Watch List.
Look What We Found!
We launched the Psychedelic Stock Review a little more than a year ago and decided...
Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.
Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion)...
Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials
Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD.
Company raises $1.3M USD convertible note...
Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.
Rick Doblin, Recently Visited one of Psycheceutical's Labs.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted...
COMPASS Pathways (CMPS) Announces Up to $285 Million Private Placement
Transaction led by healthcare specialist investors, TCGX and Aisling Capital
$125 million financing upfront with up to...
I Use Ketamine for Depression – Here’s How It Works.
FREETHINK: When first manufactured as an anesthetic for humans and animals in 1962, doctors had no intention of prescribing ketamine for depression....
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel Topical Ketamine Delivery.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs